

Aptima Combo 2[®] Assay for CT/NG

Targeting RNA for the enhanced detection of multiple targets.

The Aptima Combo 2[®] assay provides excellent diagnostic performance across a broad range of specimen types from both patient and clinician collected samples.

Aptima [®] Multitest Swab Collection Kit			Aptima [®] Urine Collection Kit	Aptima [®] Unisex Swab Collection Kit	
Vaginal	Throat	Rectal	Female/Male urine	Endocervical	Male urethral
✓	✓	✓	✓	✓	✓

PreservCyt[®] solution collection also available.¹

One sample, multiple STI results

Clinically relevant sample type options makes the Aptima Combo 2 assay for CT/NG easy to order as a standalone or in combination with the Aptima[®] Mycoplasma genitalium assay and the Aptima Trichomonas vaginalis assay or with the ThinPrep[®] Pap Test.*



Aptima Multitest Swab Kit



Aptima Urine Kit



Aptima Unisex Swab Kit



ThinPrep Pap Test Vial

*Refer to individual assay package inserts for cleared specimen types and performance claims.

Aptima Combo 2[®]
Assay for CT/NG

The Aptima Combo 2[®] assay for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* uses target capture of rRNA with proven detection for improved patient care.

- Provides an upfront biological advantage compared with assays that detect DNA—up to 1,000-fold more rRNA than DNA per cell.²
- Dual Detection probes to detect all known CT variants and provide additional diagnostic protection against future genetic evolution.
- Minimises false negatives by removing potential amplification inhibitors.³
- Aptima[®] CT and Aptima GC assays with different target available to confirm positive results on same instrument.
- Used as reference method in peer reviewed publications.
- Allows multiple sample types to be run simultaneously increasing flexibility.

Excellent detection across specimen types

The Aptima Combo 2 assay demonstrated the same excellent sensitivity and specificity for CT and NG detection for each specimen type when compared with an infected status algorithm.³

Aptima Combo 2 assay

Specimen type	CT*		NG†	
	Sensitivity	Specificity	Sensitivity	Specificity
Clinician-collected vaginal swab/ Patient-collected vaginal swab ³	97.2%	98.5%	97.7%	99.6%
Endocervical swab ³	97.2%	99.3%	100.0%	99.8%
Male urethral swab ³	100.0%	99.1%	100.0%	100.0%
Male urine ³	95.2%	99.8%	98.7%	99.7%
Female urine ¹	94.7%	98.9%	91.3%	99.3%
PreservCyt [®] Solution ¹	96.7%	99.2%	92.3%	99.8%

*The infected status algorithm was based on assay results from AC2 Tigris[®], ACT Tigris and AC2 Panther[®].

†The infected status algorithm was based on assay results from AC2 Tigris, ANG Tigris and AC2 Panther.

The Aptima Combo 2 assay demonstrates up to 100% sensitivity and specificity in detecting CT/NG from throat and rectal swabs.¹

RUN ON
PANTHER[®]



References: 1. Aptima Combo 2 package insert AW-19693-001, San Diego, CA; Hologic, Inc., 2020. 2. Chernesky M, Jang D, Luinstra K, et al. High analytical sensitivity and low rates of inhibition may contribute to detection of *Chlamydia trachomatis* in significantly more women by the APTIMA Combo 2 assay. *J Clin Microbiol.* 2006;44(2):400-405. 3. Aptima Combo 2 Assay (Panther system) package insert, # 502446-IFU-PI_001_01-RevC, San Diego, CA; Hologic, Inc., 2013.

Diagnostic Solutions | Hologic.com | euinfo@hologic.com

SS-00268-EUR-EN Rev 006 © 2020 Hologic, Inc. All rights reserved. Hologic, Aptima, Aptima Combo 2, Panther, PreservCyt, ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to euinfo@hologic.com.